Aiforia signs agreement with South Korean biotech company to augment its novel drug discovery platform with AI
Aiforia and Genuv will collaborate to to integrate Aiforia’s deep learning AI into Genuv’s ATRIVIEW® discovery platform for neurodegenerative diseases.The two companies announced an agreement to add Aiforia’s artificial intelligence technology to Genuv’s ATRIVIEW® proprietary drug discovery platform, used to screen both existing drugs and new substances for neuroprotective and neuroregenerative effects. ATRIVIEW® was used to discover Genuv’s leading drug candidate, SNR1611, which has shown the ability to restore CNS function in preclinical models of amyotrophic lateral sclerosis (ALS) and